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e-mail address: ophtheg@emory.edu (H.E. Grossniklaus).Kristen P. Jijelava, BS; Hans E. Grossniklaus, MD, MBA ⇑AbstractDiffuse anterior retinoblastoma is a rare variant of diffuse infiltrating retinoblastoma which occurs in up to 1–2% of cases of ret-
inoblastoma. In diffuse anterior retinoblastoma there is a small focus of tumor in the peripheral retina from which free tumor cells
enter the aqueous humor and implant on the ciliary body, iris, lens and trabecular meshwork. Patients most commonly present with
pseudouveitis, pseudohypopyon and increased intraocular pressure. The differential diagnosis is broad and all of the reported
cases relied upon aspirates from the aqueous humor in order to make the diagnosis prior to proceeding with treatment. Treatment
involves enucleation and, depending upon the extent of the tumor, may require systemic chemotherapy or external beam radia-
tion. This review summarizes the 7 previously reported cases of diffuse anterior retinoblastoma, discusses pathologic features, and
addresses the challenges of early diagnosis and future directions.
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The most common primary intraocular malignancy in chil-
dren is retinoblastoma. Retinoblastoma comprises 2–4% of
all childhood tumors and has an annual incidence in the
United States of 11.8 per million in children under the age
of four.1,2 Retinoblastoma can be classified as sporadic or
familial and as unilateral or bilateral.3 In familial cases, par-
ents carrying a mutation of the RB1 gene (13q4) have a
50% chance of passing the mutant allele onto their offspring
and 40% of those who inherit the mutant allele will develop
retinoblastoma.4 The tumors are unifocal or multifocal, dis-
crete yellow–white retinal masses with prominent feeding
vasculature.5 Growth patterns of retinoblastoma include
endophytic, exophytic, mixed endophytic-exophytic, and
diffuse.4,6 Endophytic retinoblastomas grow from the inner
retina toward the vitreous and exophytic tumors grow from
the outer retina toward the choroid.6
Diffuse infiltrating retinoblastoma is a rare growth pattern
that occurs in 1–2% of retinoblastoma cases in which the tu-mor grows horizontally with minimal vertical growth. This
form is the most difficult to diagnose as there is no well-
defined retinal mass and it can mimic an inflammatory pro-
cess.7 These tumors tend to be unilateral, sporadic, and more
commonly occur in children around the ages of 6–8 years.8
Diffuse anterior retinoblastoma, an uncommon variant of dif-
fuse infiltrating retinoblastoma, results from a small focus of
intraretinal tumor at the far periphery of the retina which
seeds tumor cells into the aqueous humor in the region of
the vitreous base and ciliary body.4 As a result, these tumors
tend to resemble uveitis and diagnosis is often delayed.Historical review
Diffuse infiltrating retinoblastoma was first described al-
most two centuries after Hayes described a neuroepiblastic
tumor of the retina, later referred to as retinoblastoma, in
1767.9 While Schofield published the first case titled ‘‘Diffuse
infiltrating retinoblastoma’’ in 1960, it was Ashton who ise:
al.com
States.
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tion with Schofield in 1958.9 Two similar cases representing
likely diffuse infiltrating retinoblastoma had previously been
described by Manschot in 1956 and Weizenblatt in 1957.9
Reeser presented the first case of what would later be called
diffuse anterior retinoblastoma at the Verhoeff Society meet-
ing in April of 1975.6 Garner et al. published the first case re-
port in 1987 of a 7 year old girl with unilateral retinoblastoma
that was initially misdiagnosed as granulomatous uveitis since
no retinal mass was seen on examination to suggest retino-
blastoma. However, two small foci of tumor at the far periph-
ery of the retina were later identified under microscopy.10
Grossniklaus et al. were the first to suggest the name ‘‘Dif-
fuse Anterior Retinoblastoma’’ in their case report of a 6 year
old child with unilateral retinoblastoma which was also ini-
tially misdiagnosed as Toxocara endophthalmitis.7 Overall a
total of seven cases have been reported.4,6–8,10–12 Out of
these seven cases, only one germline mutation of the RB1
gene mutation has been reported. This is significant because
up until 2009, it was believed that diffuse anterior retinoblas-
toma was a sporadic form of retinoblastoma, but Crosby et
al. showed that this form may in fact be heritable.4
Clinical presentation
Diffuse anterior retinoblastoma is a unilateral form of reti-
noblastoma that affects males and females at equal rates
and is usually diagnosed in children between 5 and 12 years
of age.7 The average age of diagnosis based upon the seven
previously reported cases is 6.4 years (Table 1). Most com-
monly, children present with pseudouveitis, pseudohypopyon
and increased intraocular pressure.11 Slit-lamp examination is
likely to show a prominent cellular reaction in the anterior
chamber, keratic precipitates, and white fluffy exudates mim-
icking a hypopyon (Fig. 1). The dilated fundus exam is likely to
be normal as only 1 case report identified a small peripheral
retinal mass that was visible on examination.4 Concordantly,
B-scan echography did not reveal a retinal mass or calcifica-
tion in any case reports. Two of the seven reported cases were
initially misdiagnosed due to a lack of well-defined retinal
mass and the tumor cells mimicking an inflammatory pro-
cess.7,10 The differential diagnosis for diffuse anterior retino-
blastoma is broad and includes medulloepithelioma,
sarcoidosis, idiopathic uveitis, metastatic neuroblastic tumor,
fungal endophthalmitis, pars planitis, Toxocara endophthal-
mitis, leukemia, lymphoma, juvenile rheumatoid arthritis-
associated uveitis, and retinoblastoma.8 While it is widely
known that fine-needle aspiration biopsy (FNAB) is contraindi-
cated in known cases of retinoblastoma, each of the published
cases performed a FNAB of the anterior chamber infiltrate
through the clear cornea in order to narrow the differential
and make the diagnosis.4,7,8,10–12 It should be emphasized
that a FNAB should only be performed as a last resort due
to the risk of seeding viable tumor cells along the needle tract,
as was reported by Langmuir et al.8
Pathology
On gross examination, white fluffy material can be seen
within the anterior chamber coating the iris, pars plicata, pars
plana and lens zonules as described in the case reports
(Fig. 2). It may also be possible to see white material in thevitreous base. Only one case report described a small
focus of retinal tumor located close to the ora serrata that
could be identified on gross examination of the enucleated
specimen.4
On microscopic examination, round basophilic tumor cells
are likely to be seen infiltrating 360 around the lens zonules,
ciliary smooth muscle, and iris stroma (Fig. 3). Tumor cells can
also be seen diffusely throughout the anterior chamber, in
the anterior vitreous, as well as lining the posterior cornea.
In each case, the patients presented with increased intraocu-
lar pressure which can be explained by the combination of
neovascularization of the iris and infiltration of tumor cells
into Schlemm’s canal and the trabecular meshwork (Fig. 4).
In Longmuir et al., tumor cells were even seen invading into
the inner portion of the sclera along the region of the angle.8
Numerous pyknotic and necrotic nuclei can be seen in addi-
tion to stippled and hyperchromatic nuclei. Homer Wright ro-
settes, a ring of nuclei around a tangle of neural filaments
with no central lumen, were present in two cases.4,8 Similarly,
Flexner-Wintersteiner rosettes, a ring of columnar cells sur-
rounding a central lumen, were present in two cases.8,11
From the published cases, 50% of cases identified a small
focus of retinal tumor under microscopy while no retinal tu-
mor could be identified in the other half case reports. When
retinal involvement was detected, the tumors were located at
the far periphery of the retina close to the ora serrata and
minimal thickening of the retina was noted. Initially no retinal
involvement was identified in Garner et al., but after examin-
ing multiple levels, 2 small foci of tumor, each less than
1.5 mm in total diameter, were identified at 11–12 o’clock
and 6–7 o’clock meridians.10 Similarly, after examining serial
step sections, Grossniklaus et al. identified a small intraretinal
tumor at the periphery of the retina.7 Crosby et al. reported
the largest known intraretinal tumor in diffuse anterior retino-
blastoma, which still only measured 3  1 mm, and did not in-
vade into either the pigment epithelium or the choroid.4
Longmuir et al. examined 487 slides of 4 lm sections, Herwig
et al. examined 422 sections, and Khetan et al. examined an
unreported number of serial sections, and no retinal focus
was identified in any of these cases.8,11,12 Possible explana-
tions for a lack of intraretinal tumor include recession or invo-
lution of a small focus of retinal tumor by the time of
enucleation, a retinal tumor so small that it was missed on se-
rial sections, or lastly that the tumors arose from a stem cell
located within the anterior segment.8,11
Varying immunohistochemical stains were performed on
the tissue specimens in each case report and the results were
consistent between all case reports that used a given stain.
For example, neuron specific enolase (NSE), which stains cells
of neuronal origin, was positive in each of the three case re-
ports that used the NSE stain.7,10,11 Likewise, synaptophysin
was positive in two cases indicating that neuronal differentia-
tion was present.8,11 Vimentin, which stains cells that have
undergone epithelial-to-mesenchymal transition, was posi-
tive in Grossniklaus et al.7 The remainder of the stains that
were tested was found to be negative. S-100 stains schwann
cells and was negative in three case reports.7,10,11 Glial fibril-
lary acidic protein (GFAP), mouse monoclonal anti-cytokera-
tin (MAK-6), AE1, AE3, leukocyte common antigen, and
cluster of differentiation molecule 34 (CD34) each stained
negatively in one case report.7,8,10 On electron microscopy,
tumor cells have a high nuclear-to-cytoplasmic ratio, rare
Table 1. Published cases of diffuse anterior retinoblastoma through 2012.
Article
author (Year)
Eye Age/
Sex
Presenting
symptom
Eye exam US imaging Diagnosis Treatment Retinal
involvement
under
microscopy
Immuno-
histochemical
stains
Follow-up
Anterior segment Posterior
segment
Garner et al.
(1987)
OD 7yo/
F
Redness,
Blurring of
vision
‘‘Severe anterior
uveitis with large
iris nodules and
cells and opacities
in the anterior
viteous’’
– – Biopsy of
iris, lens
excision
Topical corticosteroids, oral
prednisone 5 mg TID, sub-
Tenon’s injection of
methylprednisolone, lens
excision, enucleation, orbital
radiotherapy, adjuvant
chemotherapy
2 foci at
extreme
periphery of
retina,
minimal
thickening,
<1.5 mm in
diameter
+NSE, S100,
GFAP
Recurrent
orbital
retinoblastoma
8 mos after
enucleation; No
sign of further
recurrence at
12 mos
Grossniklaus
et al.
(1998)
OD 6yo/
F
Unknown Keratic
precipitates,
4 + cells,
IOP28 mmHg
Normal
appearing
retina,
cells in
inferior
vitreous
Posterior
vitreous
detachment,
no retinal
abnormality
Anterior
chamber
fine
needle
aspiration
biopsy
Topical prednisolone,
dexamethasone 0.1%,
betaxolol HCl 0.5%,
Thiabendazole for 3 days, oral
prednisone
Intraretinal
tumor in
peripheral
retina
+NSE, +
vimentin, -MAK-
6, -AE 1,3, -
GFAP, -S-100
protein
Unknown
4 + cells,
small
‘‘hypopyon’’,
IOP
34 mmHg
1–2 + Vitreous
cells
Topical prednisolone q1–2H,
Dorzolamide HCl TID, Timolol
maleate 0.25% qHS, Diclofenac
sodium QID, dexamethasone
qHS
4 + cells,
dense
‘‘hypopyon’’
4 + vitreous cells Rimexolone q1–2H, alpha
clonidine 0.5% TID
– – Enucleation
Crosby et al.
(2009)
OS 9yo/
F
Blurry vision,
redness,
discoloration
of iris
Pseudohypopyon,
IOP 34 mmHg
‘‘Possible
small,
inferior,
peripheral
mass in
her left
retina’’
– Anterior
chamber
fine
needle
aspiration
biopsy
Enucleation 3  1 mm
tumor in
peripheral
inferior
retina
Tumor Seeds: +
TGF-b, + VEGF,
-iNOS, -HIF1a
Unknown
Retina: + VEGF,-
iNOS, -HIF1a
Longmuir
et al.
(2010)
OD 8.5
yo/
M
Unknown 3–4 + cells, IOP
46 mmHg, ‘‘less
prominent flare’’,
small hypopyon,
multiple nodules
on iris
Normal
appearing
retina
Iris root
thickening to
1 mm for
360, ‘‘mild
anterior
vitreous
opacities’’
Anterior
chamber
fine
needle
aspiration
biopsy
Topical prednisolone 1% q1H,
topical dorzolamide HCl,
Timolol maleate, Brimonidine,
Scopolamine HBr 0.25%, oral
prednisone 30 mg PO q day,
Enucleation, 6 cycles of
vincristine, carboplatin,
etoposide, external beam
radiation (4140 cGy total)
No retinal
involvement
identified on
487 slides
+Synaptophysin
, - Leukocyte
common
antigen, -CD34
No recurrence
at 5 years
Khetan et al.
(2011)
OS 3yo/
F
‘‘Unresolving
anterior
uveitis with
secondary
glaucoma’’
Conjunctiva l
congestion, pupil
sluggishly reactive
to light, ‘‘white,
fluffy exudates’’,
IOP 31 mrnHs
Normal
appearing
retina
Normal Anterior
chamber
fine
needle
aspiration
biopsy
Topical prednisolone 1% q4H,
Homatropine BID, Timolol
maleate 0.5% + Brimondine
acetate 0.2% BID, Enucleation
No retinal
involvement
identified
Unknown No recurrence
at time of
publication
Herwig et al.
(2011)
OS 3yo/
M
Discoloration
of iris
Pseudohypopyon,
IOP 26 mmHg
Normal
appearing
retina
No mass or
calcification
Anterior
chamber
fine
needle
aspiration
biopsy
Enucleation, 6 cycles of
carboplatin, etoposide,
vincristine
No retinal
involvement
identified
+Synaptophysin
,+NSE,-S-100
No recurrence
at 5 mos
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Figure 1. Slit lamp appearance of diffuse anterior retinoblastoma. A
white pseudohypopyon is present (arrowhead). There are also aggre-
gates of white, fluffy tumor on the posterior corneal surface (arrow). The
eye is otherwise white and quiet.
Figure 2. Gross appearance of enucleated eye with diffuse anterior
retinoblastoma. There is white, fluffy material forming a corona around
the lens. This represents tumor in the space between the anterior hyaloid
face and ciliary body.
Figure 3. Diffuse anterior retinoblastoma in the posterior compartment.
Tumor (asterisks) is present between the anterior hyaloid face (arrow-
heads) and the ciliary body. Tumor has percolated through the pupil and
lodged in the peripheral anterior chamber (arrow). (Hematoxylin and
eosin, 10X).
Figure 4. Diffuse anterior retinoblastoma in the anterior chamber. Tumor
(arrow) is in the peripheral anterior chamber and plastered against the
posterior corneal surface. There is neovascularization of the iris (arrow-
head) present. Tumor has also infiltrated the trabecular meshwork
(asterisk). (Hematoxylin and eosin, 100X).
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intracytoplasmic filaments, chromatin clumping, and cilia in
the 9 + 0 configuration that is characteristic of retinoblas-
toma and retinal photoreceptors.7,10Cell signaling & survival mechanisms
Crosby et al. investigated the cell signaling and cell sur-
vival mechanisms involved in diffuse anterior retinoblastoma
by performing a series of immunofluorescent stains on the
intraretinal tumor and on tumor cells in the aqueous humor.4
The immunofluorescent stains that were chosen stained for
tumor growth factor b (TGF-b), vascular endothelial growth
factor (VEGF), inducible nitric oxide synthase (iNOS), and hy-
poxia inducible factor 1 (HIF1). TGF-b can have opposing ef-
fects on tumor growth dependent upon the type of cell and
the genotypic phenotype of the proteins acting in the signal
transduction pathway.4 For example, through effects on cy-
clin-dependent kinase inhibitors, the RB1 gene can regulatethe expression of TGF-b. TGF-b can have tumor suppression
effects by affecting cell apoptosis, replication potential and
proliferation.4 Alternatively, TGF-b can promote tumor
growth by aiding tumor cell invasion, migration, and angio-
genesis.4 The authors also stained for VEGF, a signaling
protein in the tyrosine kinase platelet-derived growth factor
family that is involved in vasculogenesis, angiogenesis and
survival of the cell.4 iNOS is an enzyme that converts
L-arginine to nitric oxide in order to mediate angiogenesis,
malignant transformation, and metastasis. When the retina
becomes ischemic, iNOS is expressed thereby modulating
intraretinal angiogenesis to intravitreal angiogenesis.4
Lastly, HIF1 is a transcription factor that serves as the main
mediator in hypoxic environments that serves to promote
angiogenesis.4
In Crosby et al., the tumor seeds located in the aqueous
humor stained positive for TGF-b and VEGF but were nega-
Diffuse anterior retinoblastoma: A review 139tive for iNOS and HIF1. Interestingly, the intraretinal tumor
only stained positive for VEGF and was negative for TGF-b,
iNOS and HIF1. The authors theorize that the expression of
VEGF in the intraretinal tumor was likely not secondary to
ischemia as iNOS and HIF1, components of the most com-
mon ischemic pathway, were negative.4 They also propose
that the tumor seeds in the aqueous humor acquired expres-
sion of TGF-b as a survival mechanism to aid in tumor migra-
tion and invasion. This neoplastic transformation occurs when
tumors acquire the capability to evade cell apoptosis, repli-
cate limitlessly, evade antigrowth signals and produce self-
sufficient cell signaling and angiogenesis.4
Treatment
Secondary to early misdiagnosis, the majority of patients
in the case reports received a mixture of topical corticoste-
roids and medications to lower the intraocular pressure ini-
tially. An enucleation of the affected eye was performed in
all cases ranging from 1 day (Longmuir et al.) up to 6 weeks
(Khetan et al.) after the diagnosis of diffuse anterior retino-
blastoma was made.8,12 Two case reports performed 6 cycles
of systemic chemotherapy with carboplatin, etoposide and
vincristine,8,11 and in one of those cases external beam radi-
ation to the eye socket for a total of 4140 cGy was given.8
There is only one case reported in which there was a recur-
rence of the tumor approximately 8 months following enucle-
ation.10 The patient presented with orbital swelling and an
enlarging orbital mass that was treated with radiotherapy
to the eye socket in addition to three courses of adjuvant
chemotherapy.10 At 12 months, the patient was alive with
no further signs of recurrence or metastatic disease.10 No
recurrences of tumor were reported in any of the other case
reports, and at the time of publication, all of the patients in
the case reports were alive.4,7,8,11,12 It is difficult to extract
an accurate survival rate from the reported cases as long-
term follow up for the patients is not known but the lack of
known recurrences at the times of publication is reassuring.
However, the survival rate inclusive of all variants of diffuse
infiltrating retinoblastoma has been reported and was found
to be greater than 95% in children who receive an enucle-
ation of the affected eye.13
Future directions & challenges
One of the most significant challenges in the management
of patients with diffuse anterior retinoblastoma is making the
correct diagnosis. Since this variant of retinoblastoma is
extremely rare, misdiagnosis is common as the absence of
an obvious retinal mass leads to clinical confusion. Diffuse
anterior retinoblastoma can mimic a number of more com-
mon conditions including granulomatous uveitis as in Garner
et al., Toxocara endophthalmitis as in Grossniklaus et al.,
or juvenile xanthogranuloma or tuberculosis as cited in
Spencer.6,7,10 In addition, the reported cases relied upon a
FNAB in order to make the diagnosis, which is contraindi-
cated in known cases of retinoblastoma. Khetan et al. com-
mented that in their experience ultrasonography was also
not especially helpful as it failed to show any calcifications,
retinal masses or other features of typical retinoblastoma.12
To further complicate the situation, physicians want confirma-
tion of the diagnosis prior to advising the recommendedtreatment of enucleation to families. Similarly, parents are
likely to opt for a confirmatory test, such as a FNAB, despite
the risk of tumor spread prior to proceeding with an irrevers-
ible treatment that is associated with extremely high morbid-
ity and decreased quality of life if the diagnosis of diffuse
anterior retinoblastoma was incorrect. In the future, it would
be ideal to develop a diagnostic tool that could be used to
confirm the diagnosis that had minimal to no risk of tumor
dissemination.
Conclusions
Diffuse anterior retinoblastoma is an uncommon variant of
diffuse infiltrating retinoblastoma that occurs unilaterally in
children between the ages of 3 and 9 years. The majority of
cases are nonhereditary, however there is one reported case
in a child with a germline mutation of the RB1 gene. Since the
tumor can masquerade as a variety of conditions, diffuse
anterior retinoblastoma should be considered in all cases of
refractory uveitis in children. Fine needle aspiration biopsy
should only be performed at highly specialized centers with
experienced ophthalmologists and ophthalmic pathologists
as a last resort to narrow the differential diagnosis due to
the risk of tumor dissemination. Treatment involves enucle-
ation of the involved orbit and in some cases may require
external beam radiation or systemic chemotherapy.
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